Question-and-Answer Session
Operator
Right, thank you. (Operator instructions) And our first question comes from Pamela Bassett from Cantor Fitzgerald. Please go ahead.
Pamela Bassett – Cantor Fitzgerald
Hi, thanks for taking my call.
Sharon Tetlow
Hi, Pamela.
Pamela Bassett – Cantor Fitzgerald
Hi. I’m wondering – should we expect more repurchases of the convertible notes going forward? And I apologize, maybe I joined the call little late, maybe you addressed this in the –
Steve Sherwin
No, we haven’t said anything specifically, and we may or may not do something along those lines.
Sharon Tetlow
I mean – hi, Pamela, it’s Sharon.
Pamela Bassett – Cantor Fitzgerald
Hi, Sharon.
Sharon Tetlow
I mean, obviously right now cash is extremely important to us. So we’ll be thoughtful about that in all alternatives.
Pamela Bassett – Cantor Fitzgerald
Okay. And I mean, you laid out some of the possibilities for strategic alternatives. Is – let me, clearly having that cash is important and useful in creating a new opportunity. Where might – there are so many assets available currently at pretty good prices. Can you talk about what criteria you might use in making a choice, by acquisition or by another company or reverse merger or something along those lines?
Steve Sherwin
Well, as I mentioned, all of the possible alternatives are under evaluation. And one category is just as you are suggesting, the acquisition of products or potentially technologies that would take the company in a new direction. And again, just to restate something that I commented on earlier, what will drive that is our best assessment of the value for our stakeholders. Having said that, just to be a little more specific about assets that might be of interest to us, we would pay a lot of attention to opportunities that get to inflection points in value within a timeframe that is supported by the available cash going forward. In other words, we would be thinking very carefully about maintaining as much independence as possible from the capital markets on the other side of any theoretical asset acquisition. So, stage of development would be a consideration. Beyond that, obviously our space, if you will, and biotech is in the oncology area, but of course there is nothing unique about us in that regard. There are many such companies. And that’s really all I can say at this point I think.
Pamela Bassett – Cantor Fitzgerald
- To read the full transcript on Seeking Alpha, click here »
